CRP and COVID-19: The ability of ACHE and CLEC12A to discriminate between a favorable and unfavorable outcome for COVID-19 patients showed better performance than that of existing biomarkers, like CRP and PCT independent of the sampling time, and better than the SOFA score at day 0.